Our Take
The ISS shutdown is real; the private space lab ecosystem to replace it is still speculative.
Why it matters
Pharmaceutical companies have used microgravity environments on the ISS for protein crystallization, cell growth, and early-stage drug candidate screening. Losing access without a ready alternative means months or years of disrupted research pipelines for companies like Merck.
Do this week
Pharma R&D leaders: audit which compounds or assays currently depend on ISS microgravity by Q2 2025 so you can identify which can migrate to ground-based alternatives versus which require private orbital capability.
NASA ends ISS operations, creating a research gap
NASA is preparing to decommission the International Space Station, ending decades of on-orbit pharmaceutical research. The agency has not yet announced a firm retirement date, but the timeline is public and approaching. Drug makers, biotech firms, and aerospace startups are responding by developing private space labs intended to fill the void.
Merck and other major pharmaceutical names have used ISS facilities—specifically the National Lab partnerships—to conduct experiments in microgravity that would be difficult or impossible on Earth. The work includes protein crystal growth for structural drug design and cell culture studies that benefit from the absence of gravity.
Private competitors are already positioning themselves. Axiom Space, Orbital Reef, and other commercial space companies are designing modular laboratory modules capable of hosting life sciences payloads. No private facility has yet matched the scale, duration, or scientific track record of the ISS, and no commercial alternative is yet operational.
Continuity risk in early-stage drug discovery
The ISS closure creates a 2-5 year window of uncertainty during which access to microgravity will be unavailable or severely constrained. Pharmaceutical workflows that depend on space-based assays will face delays. Early-stage candidates in Phase 1 or preclinical development may slip timelines; companies with compounds in later stages may need to find workarounds or pause certain lines of inquiry.
Private orbital labs will eventually fill this gap, but they will likely be more expensive, less reliable, and less flexible than the ISS has been. Costs per experiment may rise. Access may be rationed by launch frequency and commercial demand. The transition is not a seamless handoff; it is a disruption with winners and losers.
Startups and smaller drug makers may be priced out of space-based research entirely, shifting competitive advantage toward companies with enough cash to subsidize private orbital access or to shift assay work to ground-based proxies.
Audit your microgravity experiments now
Identify which R&D programs absolutely require microgravity versus which can be redirected to terrestrial methods (centrifuges, suspension bioreactors, engineered cell culture systems). Run proof-of-concept tests on ground-based alternatives before ISS access ends. Model the cost and timeline impact of renting seats on private orbital facilities when they launch, and factor that into your budget forecasts for 2026 onward.
For compounds in early preclinical phases, the delay is manageable. For assets in Phase 1 or Phase 2 human trials, delays compound. Begin conversations with ISS National Lab program officers now to understand sunset dates and transition options. If your compound genuinely requires orbital microgravity and has no terrestrial proxy, lock in access to emerging private platforms (Axiom, Orbital Reef) while seats are still available and pricing is being established.
Do not assume continuity. Plan for a 18-36 month gap in microgravity access. That gap will shape which programs advance and which are shelved.